title: First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
abstract: BACKGROUND
  First-line bevacizumab-paclitaxel therapy demonstrated a median progression-free survival (PFS) of 11 months in three randomized phase III trials on metastatic breast cancer (mBC) (E2100, TURANDOT and CALGB 40502). We assessed the efficacy and safety of bevacizumab-paclitaxel in a routine oncology practice study.
  
  
  METHODS
  Patients with previously untreated mBC received bevacizumab-paclitaxel according to the approved indication in Hungary. The primary end-point was PFS. Secondary end-points included time-to-treatment discontinuation, 1-year survival rate, PFS in patients with triple-negative breast cancer (TNBC) and safety.
  
  
  RESULTS
  Median PFS in the 220 treated patients was 9.3 (95%CI 7.8-10.8) months. The 1-year survival rate was 68%. In patients with TNBC (N=106), median PFS was 8.3 months (95%CI 7.8-8.8). Adverse events were consistent with the established safety profile of bevacizumab-paclitaxel.
  
  
  CONCLUSIONS
  Bevacizumab-paclitaxel is an active and well-tolerated first-line treatment for mBC, with notable activity in TNBC.
authors.affiliation: Semmelweis University, 1st Department of Internal Medicine, Oncology Section; Tömő u. 25-29, 1083 Budapest, Hungary. magdolna.dank@gmail.com.
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
authors.forename: Laszlo
authors.initials: L
authors.lastname: Budi
authors.forename: Bela
authors.initials: B
authors.lastname: Piko
authors.forename: Laszlo
authors.initials: L
authors.lastname: Mangel
authors.forename: Jozsef
authors.initials: J
authors.lastname: Erfan
authors.forename: Jozsef
authors.initials: J
authors.lastname: Cseh
authors.forename: Agnes
authors.initials: A
authors.lastname: Ruzsa
authors.forename: Laszlo
authors.initials: L
authors.lastname: Landherr
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage*; D010818:Practice Patterns, Physicians'; D011379:Prognosis; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel
keywords: Bevacizumab; first-line; observational study; triple-negative breast cancer